Nivolumab (Opdivo, Bristol-Myers Squibb Company), IgG4 anti-PD-1 monoclonal antibody was approved by the FDA and EMA (2015) for treatment of both squamous and non-squamous NSCLC, and as second-line therapy in patients with metastatic NSCLC (153). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.